Answers are grounded in this paper and cite their sources.
Cross-population study evaluates deep learning models for referable diabetic retinopathy detection, indicating the need for local validation.
Purpose: To evaluate cross-population performance of deep learning models for referable diabetic retinopathy (DR) detection and assess whether inclusion of local data improves robustness in a Turkish external validation setting. Methods: Global datasets (DDR, IDRiD, Messidor) and a Turkish real-world clinical dataset were used. Images were re-graded by three ophthalmologists and binarized as referable/non-referable DR. Five architectures were evaluated: EfficientNet-B0, EfficientNet-V2, ResNet50, ConvNeXt-V2-Tiny, and Swin V2 CR Small. Models were tested under three settings: Global Train–Global Test, Global Train–Local Test, and Mixed Train–Mixed Test. Performance metrics included accuracy, sensitivity, specificity, NPV, ROC-AUC, and PR-AUC; Grad-CAM was used for explainability. Results: The global training set included 9,881 images; two external test sets (2,042 images each) were used. Inter-grader agreement was high (ICC[3,1]=0.84; ICC[3,k]=0.96). Swin V2 CR Small achieved the highest performance in Global Train–Global Test (accuracy 0.938; ROC-AUC 0.985). Performance declined in Global Train–Local Test, where ConvNeXt-V2-Tiny performed best (accuracy 0.823; sensitivity 0.940; ROC-AUC 0.913). In Mixed Train–Mixed Test, ConvNeXt-V2-Tiny remained the most balanced model (accuracy 0.823; sensitivity 0.939; NPV 0.948; ROC-AUC 0.875). Conclusion: Models performed strongly under matched conditions but degraded across populations. ConvNeXt-V2-Tiny showed the most stable screening performance, supporting the need for local validation before deployment.
No takes yet. Share an insight, caveat, or question.
Engin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: